Aliso Viejo, CA, USA, April 05, 2011 / b3c newswire / – Ambry Genetics announced today that it is the first authorized customer service provider (CSP) in Ion Torrent’s new service provider program. Ion Torrent’s CSP certification assures customers that the organization they are trusting with their samples has been trained and tested by Ion Torrent to produce the highest quality sequence data.
Ion Torrent has revolutionized DNA sequencing by enabling a direct connection between chemical and digital information through the use of proven semiconductor technology. The result is a sequencing system that is simpler, faster, less expensive and more scalable than other sequencing technologies.
The Ion Torrent Authorized CSP Program gives scientists an easy way to take advantage of the speed and affordability of Ion semiconductor sequencing.
“We’ve been generating data with the Ion Personal Genome Machine (PGM™) for six months and are excited about launching services on this platform and being the first customer service provider,” said Charles Dunlop, CEO of Ambry Genetics. “This machine has the ability to change the way sequencing is done.”
“Ever since the launch of the Ion PGM sequencer, we have gotten numerous requests to sequence various types of samples,” said Ardy Arianpour, Vice President of Business Development at Ambry Genetics. “We are currently taking orders and lining up customers who want to experience the Personal Genome Machine.”
“Ambry Genetics was one of our first early access sites and now we are very pleased to have them as our first Ion Torrent Authorized Customer Service Provider for the Ion PGM,” said Maneesh Jain, Vice President of Marketing and Business Development.
Click the link below to view the special video announcement!
http://www.youtube.com/watch?v=Kg9D4zEC16M
Or to view it in HD click below.
http://www.youtube.com/watch?v=Kg9D4zEC16M&hd=1
About Ambry Genetics - www.ambrygen.com
Ambry Genetics is a CAP-accredited and CLIA-certified commercial clinical laboratory headquartered in Aliso Viejo, California. Since the company’s inception in 2000, it has become a leader in providing genetic services focused on clinical diagnostics and genomic services. Ambry has built a solid reputation for unparalleled service, and has been at the forefront of applying new technologies to the clinical molecular diagnostics market and advancements in disease research. To learn more about testing and services available through Ambry Genetics, visit www.ambrygen.com.
About Life Technologies - www.lifetechnologies.com
Life Technologies Corporation (NASDAQ: LIFE) is a global biotechnology company dedicated to improving the human condition. Our systems, consumables and services enable researchers to accelerate scientific and medical advancements that make life even better. Life Technologies customers do their work across the biological spectrum, working to advance the fields of discovery and translational research, molecular medicine, stem cell-based therapies, food safety and animal health, and 21st century forensics. The company manufactures both molecular diagnostic and research use only products. Life Technologies' industry-leading brands are found in nearly every life sciences lab in the world and include innovative instrument systems under the Applied Biosystems and Ion Torrent names, as well as, the broadest range of reagents with its Invitrogen, GIBCO, Ambion, Molecular Probes and Taqman products. Life Technologies had sales of $3.6 billion in 2010, has a workforce of approximately 11,000 people, has a presence in approximately 160 countries, and possesses one of the largest intellectual property estates in the life sciences industry, with approximately 3,900 patents and exclusive licenses. For more information on how we are making a difference, please visit our website: http://www.lifetechnologies.com.
Media Contacts
For Ambry Genetics
Jeff Owen
949-900-5542
This email address is being protected from spambots. You need JavaScript enabled to view it.
For Ion Torrent
Wes Conard
415-385-4455
This email address is being protected from spambots. You need JavaScript enabled to view it.